abrdn plc increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 14.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 283,899 shares of the biopharmaceutical company's stock after buying an additional 35,588 shares during the period. abrdn plc owned about 0.37% of Xenon Pharmaceuticals worth $11,129,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently bought and sold shares of the company. Jennison Associates LLC increased its position in shares of Xenon Pharmaceuticals by 39.0% during the fourth quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company's stock worth $31,421,000 after purchasing an additional 224,892 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Xenon Pharmaceuticals by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,166 shares of the biopharmaceutical company's stock worth $634,000 after purchasing an additional 1,594 shares in the last quarter. KBC Group NV increased its position in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares in the last quarter. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock worth $95,000 after purchasing an additional 1,414 shares in the last quarter. Finally, Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth $101,000. Institutional investors own 95.45% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on XENE shares. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday. They set a "buy" rating and a $67.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Finally, HC Wainwright reissued a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Xenon Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $57.38.
View Our Latest Stock Analysis on Xenon Pharmaceuticals
Xenon Pharmaceuticals Price Performance
NASDAQ:XENE traded down $0.86 during mid-day trading on Tuesday, hitting $38.39. The company's stock had a trading volume of 334,116 shares, compared to its average volume of 417,756. Xenon Pharmaceuticals Inc. has a 1 year low of $35.53 and a 1 year high of $50.99. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -13.61 and a beta of 1.20. The business's fifty day moving average is $39.91 and its two-hundred day moving average is $40.60.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same quarter in the previous year, the business earned ($0.73) earnings per share. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Sherry Aulin sold 18,709 shares of the company's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian Mortimer sold 16,315 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now owns 31,302 shares of the company's stock, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,383 shares of company stock worth $2,535,891. Company insiders own 5.52% of the company's stock.
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
